2013 - IXA 2013 Congress


Plenary 2: Hyper Immune

7.5 - DeSens KTx in Japan

Presenter: Shohei, Fuchinoue, Tokyo, Japan
Authors:


 

Desensitization protocol in HLA cross match positive kidney transplant patients in Japan

Shohei Fuchinoue, MD. PhD.
Department of Surgery, Kidney Center, Tokyo Women’s Medical University, Japan

Preexisting donor-specific antibodies against HLA are major risk factor for acute and chronic antibody mediated rejection. Most high risk patients are positive CDC cross match or positive T and /orB IgG flow cross match positive with repeat HLA mismatch from a previous transplantation. The patients with negative CDC positive T and /orB IgG flow crossmatch positive is an intermediate risk. That with positive DSA but negative flow and negative CDC crossmatch is considered to be low risk. Encouraged by the outcome of the ABO incompatible kidney transplantation in Japan, we adapted almost same desensitization protocol in HLA crossmatch positive recipients in kidney transplantation. Desensitization protocol is consisting of pretranplant immunosuppression with FK and MMF, anti-20 antibody and plasmapheresis. If CDC is positive, in spite of these treatments, we provide the next treatment with high-dose intravenous immunoglobulin (IVIG) or bortzomib. If the crossmath was negative, patients underwent transplantation. Post-transplant immunosuppression consisted of prednisone, CNI, MMF and Thymoglobulin.

Chronic antibody mediated rejection is a currently recognized as the major cause of graft loss in kidney transplantation. Although desensitization with plasmapheresis and anti-CD20 had been tested, treatment success rate was only 30%. As revised treatment to chronic antibody mediated rejection had been adapted in many institutes, result of our new protocol will be presented.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi